The medications that actually change PCOS outcomes: with evidence, doses, and monitoring
Below are detailed guides to the most important medication categories in modern PCOS care. Each section covers the evidence base, dosing, monitoring, side effect profile, and appropriate patient selection. Read what applies to your situation, then book with a gynecologist or endocrinologist to develop a personalized plan.
Metformin and Inositols: the insulin-sensitizer foundation
Metformin: Metformin is the most widely prescribed medication in PCOS and one of the most extensively studied. Originally a type 2 diabetes drug, it addresses the core insulin resistance in PCOS (present in 50-70% of patients, higher in obese phenotypes). The International PCOS Guideline 2023 recommends it as an adjunct to lifestyle in adults with PCOS, particularly for metabolic dysfunction and menstrual irregularity.
Mechanism: Metformin decreases hepatic glucose production (via AMPK activation), improves peripheral insulin sensitivity, and modestly reduces ovarian androgen production. In PCOS it improves ovulation rates (from 12% baseline to 32% on metformin in the Legro 2007 PPCOS trial), reduces free testosterone by 20-30%, improves menstrual cyclicity in 30-50% of women, and produces modest weight loss (2-3 kg average). Effects are dose-dependent and typically evident by 3-6 months.
Dosing: Start 500 mg once daily with a meal and titrate weekly to 1,000-2,000 mg/day in divided doses (500-1,000 mg twice daily or 850 mg twice daily). Extended-release (XR/SR) formulations reduce GI side effects and improve adherence. Common effective doses are 1,500 mg/day (regular) or 1,000-2,000 mg/day (XR). Maximum 2,550 mg/day. Take with meals to reduce nausea. Your doctor decides the dose for you.
Side effects: Nausea, diarrhea and abdominal discomfort (30-50% of patients initially, usually improving within weeks). Metallic taste (10%). Vitamin B12 deficiency with long-term use, so an annual B12 check is recommended. Very low risk of lactic acidosis (contraindicated in significant renal impairment, eGFR under 30). Metformin does NOT cause hypoglycemia when used alone, unlike insulin or sulfonylureas.
Monitoring: Baseline creatinine (eGFR above 45 required, caution at 30-45), repeated annually. B12 level annually if on treatment for more than 5 years. HbA1c every 6 months to monitor metabolic status. Menstrual diary and hirsutism tracking.
Inositols: Myo-inositol and D-chiro-inositol are naturally occurring compounds that act as second messengers in insulin signaling. They have accumulated substantial evidence in PCOS, improving ovulation, reducing androgens, improving egg quality, and reducing gestational diabetes risk if used pre-conception. The optimal ratio is 40:1 myo-inositol to D-chiro-inositol (mimicking the natural ovarian ratio), typically 2 g myo-inositol + 50 mg D-chiro-inositol twice daily.
Evidence for inositols: A meta-analysis (Unfer et al.) showed myo-inositol improved ovulation rate, cycle regularity, testosterone and insulin sensitivity comparably to metformin in some studies, with a much better tolerability profile. Combined with metformin, it may enhance response. It is particularly useful in lean PCOS or in metformin-intolerant patients.
GLP-1 agonists: Liraglutide, semaglutide and tirzepatide are the newer frontier for PCOS with significant obesity and insulin resistance. Evidence from obesity trials showed 10-20% weight loss (STEP trials with semaglutide). Small PCOS-specific trials show improved ovulation, cycle regularity and androgen reduction. Cost and access remain limitations in India, but availability is improving. They are not for use in women actively trying to conceive.
Who benefits most from metformin and inositols: Insulin-resistant PCOS phenotype, elevated fasting insulin or HOMA-IR above 2.5, BMI of 25 or more, acanthosis nigricans, sugar cravings or energy crashes, or PCOS with impaired glucose tolerance. Lean PCOS women without insulin resistance may benefit less from metformin but often respond well to inositols.
